Pearl Powder vs. Plain Calcium After Menopause: What a New Animal Study Found

What did the 2022 rat study actually measure?

The paper is Nguyen and colleagues, published in JBMR Plus in 2022. The researchers removed the ovaries of female rats. That drops estrogen the way menopause does in women, and bone loss begins.

For 28 days, the rats ate one of two supplements mixed into the same base diet at the same 0.25% dose. One was nacre, the pearl material. The other was ordinary calcium carbonate.

The result, in the authors' own words, was that "nacre-based diet prevented the OVX-induced bone loss better than that of the CaCO3 supplement." Four numbers carry that sentence:

• Trabecular bone volume: 35% higher in the femur (p = 0.004) and 11% higher in the lumbar spine (p = 0.01) on pearl versus calcium.
• Osteoclast surface: 1.5-fold lower on pearl (p = 0.02), meaning less of the bone surface was actively being broken down.
• CTX, a marker of bone breakdown: blunted on pearl compared to the calcium group.
• P1NP, a marker of new bone formation: raised on pearl. Bmp2, a gene that signals bone-building cells to switch on, rose 1.76-fold versus the untreated rats.

Both groups got calcium. Pearl's own aragonite is largely calcium carbonate. The difference was not more mineral. It was what the mineral was carrying with it.

Reading the numbers honestly

A 35% gap in one rat femur measurement is not a 35% gap on a woman's DEXA scan. Rat bone turns over faster than human bone, and 28 days in a rodent compresses a process that unfolds over years in a person. What the study proves is a real, statistically significant difference between two materials at the same dose, in the same animals. Nothing more.

Why would a shell material outperform calcium itself?

Nacre is not just calcium. It is calcium carbonate crystals, in the aragonite form, held inside a protein and organic matrix that the pearl-forming animal builds around them. Plain calcium carbonate supplements are the mineral alone, with no matrix.

That matrix appears to be doing work. A 1999 study in the journal Bone, by Lamghari and colleagues, packed nacre powder into 21 bone cavities cut into the lumbar vertebrae of sheep. Over 12 weeks the nacre slowly dissolved, and the cavities filled in with newly matured bone trabeculae, lined with active bone-building osteoblasts.

The same paper tested something narrower in a lab dish. A water-soluble extract of nacre, with no intact crystal structure at all, still raised the activity of bone marrow cells. The authors concluded that "nacre contains one or more signal molecules capable of activating osteogenic bone marrow cells."

Something dissolved out of the shell material is doing signaling that plain calcium carbonate does not do on its own.

Does pearl powder work on human bone cells too?

The rat and sheep data is compelling, but the strongest mechanism evidence comes from human cells in a dish. A 2015 study by Green and colleagues, published in Molecular Cells, exposed human bone marrow stem cells to nacre chips.

The cells responded by secreting alkaline phosphatase, an enzyme that marks the start of bone formation, at levels that exceeded what the same cells produced when treated with rhBMP-2. That is the bone-growth protein used clinically in spinal fusion surgery.

Within 21 days those stem cells were producing collagen types I through IV. Osteocalcin, a protein made almost exclusively by mature bone-building cells, showed up by day 7. The authors called this "premature onset of an osteoblast phenotype," meaning the stem cells were pushed to become bone-building cells faster than they normally would.

This is a lab-dish result. It does not measure bone density, and no human body was involved. It shows a plausible reason the animal results above are not a fluke, because pearl material appears to signal directly to the cells responsible for building bone, in human tissue and not only in rodents.

Can old stem cells still respond to it?

One common fear in this research is that bone-building cells simply stop responding well with age, no matter what you give them. A 2024 study in Bioengineering, by Wilson and colleagues, tested that directly.

The researchers compared bone marrow stem cells from older donors, ages 58 to 64, against cells from young donors, ages 21 to 26. As expected, the older cells lagged on their own. Proliferation was significantly lower (p < 0.0001), and nearly twice as many older cells had become senescent, meaning they had stopped dividing altogether.

Then both groups of cells were grown on a shell nacre cement. The older cells' proliferation rate caught up to match the young cells. After 14 days, the calcium and phosphorus they deposited was comparable between the two age groups, and the genes involved in bone formation, BMP2, RUNX2, ALP, and COL1A1, followed the same trend.

A 64-year-old donor's cells matched a 26-year-old's output on the same material. That single result speaks directly to the fear that it is simply too late to help aging bone respond to anything.

Where does shilajit fit next to pearl powder?

Pearl powder and shilajit are studied through two different mechanisms. Optimum's Trifecta formula pairs them rather than picking one.

Shilajit's own bone research runs through a 2022 randomized, placebo-controlled human trial by Pingali and colleagues. Every single woman in the treatment group reversed her osteoporosis in 6 months. That trial is about estrogen signaling in real postmenopausal women, a different question from the shell-material mechanism above.

Two lines of evidence, aimed at two separate parts of the same problem. That is the reasoning behind combining them, not a claim that one substitutes for the other.

What hasn't been tested yet?

None of this is a finished case. A fair reading of the literature owes you a few honest limits:

• No trial has run pearl powder against plain calcium in postmenopausal women. The 35% and 11% numbers above are from rats, not people.
• The one human bone trial on pearl powder alone, a small pilot of 30 women, found a 5.2% bone density change that did not reach statistical significance (p = 0.067).
• The stem cell studies measure lab markers, alkaline phosphatase, collagen, osteocalcin gene activity, not a finished skeleton.
• Dose has not been standardized across species. What worked in a rat diet or a lab dish has not been translated into a validated human dose-response curve for bone.

Stating those limits plainly does not erase what the animal and cell data show. It draws the line between a reproducible lab finding and a claim about your own body.

Optimum Shilajit Trifecta

If you want to see how pearl powder, bamboo silica, and Altai shilajit come together in one formula, lays out all three ingredients and the research behind each one.

See the Optimum Shilajit Trifecta